First-in human, dose escalation and cohort expansion study for the evaluation of LB-208 (HTR1B antagonist) in adult patients with relapsed or refractory solid tumours and lymphoma
Phase 1
Recruiting
- Conditions
- ymphoma, Solid tumorMedDRA version: 20.0Level: HLGTClassification code: 10025323Term: Lymphomas NEC Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-509532-25-00
- Lead Sponsor
- eukos Biotech S.L.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method